Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AA and mBC

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 18, 2023 7:13pm

137 Views

Post# 35502705

RE:RE:RE:AA and mBC

No significant obstacles since a two-arm confirmatory trial with a pelareorep + paclitaxel arm versus a paclitaxel control arm, that follows and validates an accelerated approval, would be able to be easily conducted at a reasonably inexpensive cost. Similar to Gilead's Trodelvy Phase 3 study which gained FDA approval.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?